Alpha Tau Medical Ltd. (NASDAQ:DRTS) Short Interest Up 58.8% in December

Alpha Tau Medical Ltd. (NASDAQ:DRTS) saw a significant growth in short interest in December. As of December 15th, there was short interest totaling 193,359 shares, a growth of 58.8% from the November 30th total of 121,800 shares. Based on an average daily trading volume, of 386,042 shares, the short-interest ratio is presently 0.5 days. Approximately 0.4% of the shares of the stock are short sold. Approximately 0.4% of the shares of the stock are short sold. Based on an average daily trading volume, of 386,042 shares, the short-interest ratio is presently 0.5 days.

Analysts Set New Price Targets

Several analysts have weighed in on DRTS shares. Citigroup lowered their price target on Alpha Tau Medical from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Wednesday, December 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Alpha Tau Medical in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Alpha Tau Medical to a “sell” rating in a research report on Saturday, November 1st. Finally, HC Wainwright reissued a “buy” rating on shares of Alpha Tau Medical in a research note on Wednesday, December 10th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $8.00.

Alpha Tau Medical Trading Up 1.0%

Alpha Tau Medical stock traded up $0.05 during trading hours on Friday, reaching $5.10. The company had a trading volume of 59,625 shares, compared to its average volume of 269,362. The company has a debt-to-equity ratio of 0.08, a current ratio of 8.43 and a quick ratio of 5.81. Alpha Tau Medical has a 12-month low of $2.30 and a 12-month high of $5.21. The company has a 50-day moving average price of $4.22 and a 200 day moving average price of $3.70. The firm has a market cap of $432.58 million, a price-to-earnings ratio of -9.81 and a beta of 1.06.

Alpha Tau Medical (NASDAQ:DRTS) last issued its earnings results on Thursday, November 20th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.02). Equities analysts forecast that Alpha Tau Medical will post -0.45 earnings per share for the current year.

Institutional Investors Weigh In On Alpha Tau Medical

Large investors have recently made changes to their positions in the business. Envestnet Asset Management Inc. purchased a new stake in Alpha Tau Medical in the third quarter worth $62,000. Bank of America Corp DE raised its stake in Alpha Tau Medical by 2,779.1% in the third quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock worth $101,000 after buying an additional 21,677 shares in the last quarter. Millennium Management LLC purchased a new stake in Alpha Tau Medical in the third quarter worth about $170,000. Mariner LLC lifted its holdings in Alpha Tau Medical by 185.8% in the third quarter. Mariner LLC now owns 123,250 shares of the company’s stock worth $556,000 after buying an additional 80,129 shares during the period. Finally, Levin Capital Strategies L.P. grew its holdings in shares of Alpha Tau Medical by 6.3% during the 3rd quarter. Levin Capital Strategies L.P. now owns 204,714 shares of the company’s stock worth $923,000 after acquiring an additional 12,200 shares during the period. 2.65% of the stock is currently owned by institutional investors.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.